Sunshine Biopharma Inc. Common Stock (SBFM)

FairStock Score: 44/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for businesses that earn consistent profits and possess durable competitive advantages, and Sunshine Biopharma does not fit that description. It is a $4.8 million market-cap company priced at $0.24 on 2026-10-13, with a FairStock price-to-book ratio of 0.02 and a negative P/E of -0.03. The Lynch category is none because it has lost money in each of the last four years. In fiscal FY2025, filed revenue was $36.3 million and net income was -$6.0 million; in fiscal FY2024, revenue was $34.9 million and net income was -$5.1 million; in fiscal FY2023, revenue was $24.1 million and net income was -$4.5 million. In fiscal Q2 2026, the quarter ended 2026-06-30, revenue was $9.3 million and net income was -$1.6 million, compared with revenue of $9.4 million and net income of -$1.8 million in fiscal Q2 2025. That is a smaller loss, but still a loss. Trailing free cash flow is -$5.5 million, giving a FairStock FCF yield of -115.1% against the market cap. FairStock also shows ROE of -21.92%, ROCE of -9.91%, a Piotroski F-Score of 3/9, and an Altman Z-Score of -1.76. The debt-to-equity ratio of 0.02 is low, but low leverage does not cure cash burn. The antiviral and liver-cancer pipeline is speculative, and the supplement products are not generating enough profit to cover costs. At 0.02 times book, the price looks statistically cheap, but Graham would ask whether that book value is reliable and whether continuing losses will erode it. I see no durable moat, no profitability, and a fragile financial position.

In plain English: Sunshine Biopharma is a small drug company trying to develop antiviral and cancer medicines while also selling supplements. It has lost money for years, and its sales recently shrank, so the business looks weak. The stock price is very low compared with its reported assets after debts, but that cheapness reflects real financial risk.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer